$LGND 8-K SEC Filings

Filed On	Filing
24 Sep 2026	8-K: Regulation FD Disclosure; Other Events Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
22 Sep 2026	8-K: Regulation FD Disclosure Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients
06 Aug 2026	8-K: Results of Operations and Financial Condition
14 Jul 2026	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
25 Jun 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
22 Jun 2026	8-K: Entry into a Material Definitive Agreement; Other Events
09 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
18 May 2026	8-K: Entry into a Material Definitive Agreement
07 May 2026	8-K: Results of Operations and Financial Condition
30 Apr 2026	8-K: Termination of a Material Definitive Agreement
27 Apr 2026	8-K: Entry into a Material Definitive Agreement; Other Events
26 Feb 2026	8-K: Results of Operations and Financial Condition
18 Dec 2025	8-K: Regulation FD Disclosure
06 Nov 2025	8-K: Results of Operations and Financial Condition
16 Sep 2025	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
14 Aug 2025	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
11 Aug 2025	8-K: Entry into a Material Definitive Agreement; Other Events
07 Aug 2025	8-K: Results of Operations and Financial Condition
02 Jul 2025	8-K: Regulation FD Disclosure
09 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders

Comments